1
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Risk Factors and Clinical Outcomes of Candidemia Associated With Severe COVID-19

      research-article
      , PharmD, BCPS, BCCCP, FCCM 1 , , , PharmD, BCPS, BCIDP, AAHIVP 2 , , BS, PharmD 3 , , PharmD, BCPS, BCIDP 4 , , PharmD 1 , , PharmD, BCCCP 1 , , PharmD Candidate 1 , , MD 5 , , BS, PharmD, BCIDP, BCPS 3 , , PharmD, BCCCP 6 , , MD 7 , , MD 5 , , MD 8 , , MD 5
      Critical Care Explorations
      Lippincott Williams & Wilkins
      candidemia, co-infection, COVID-19, severe acute respiratory syndrome coronavirus 2 infection

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          IMPORTANCE:

          COVID-19 can cause serious illness requiring multimodal treatment and is associated with secondary infections. Studies have suggested an increased risk of fungal infections, including candidemia following severe COVID-19 though understanding of risk factors and clinical outcomes remains unclear.

          OBJECTIVES:

          To describe clinical characteristics, outcomes and risk factors of candidemia among patients hospitalized with severe COVID-19.

          DESIGN, SETTING, AND PARTICIPANTS:

          A multicenter, case-control study of patients with severe COVID-19 was conducted to evaluate risk factors and clinical outcomes in patients who developed candidemia between August 2020 and August 2021.

          MAIN OUTCOMES AND MEASURES:

          Chart review evaluating institutional and patient demographics, clinical and mycological characteristics, concomitant interventions (antibiotics, immunosuppressive agents, parenteral nutrition, degree of oxygen support, mechanical ventilation, surgery), treatment regimens, and outcomes (length of stay and discharge disposition)

          RESULTS:

          A total of 275 patients were enrolled in the study, including 91 patients with severe COVID-19 and subsequent candidemia and 184 with severe COVID-19 without candidemia. Most patients received antibiotics prior to candidemia episode (93%), while approximately one-quarter of patients received biologic for COVID-19. In-hospital mortality was significantly higher in the cases compared with the controls (68% vs 40%; p < 0.01). Candida albicans was the most common (53%), followed by C. glabrata (19%). Use of central lines, biologic, and paralytics were independent risk factors for candidemia.

          CONCLUSIONS AND RELEVANCE:

          Candidemia following COVID-19 infection is a concern that requires clinical consideration and patient monitoring. Risk factors for the development of candidemia in the setting of COVID-19 infection are largely consistent with traditional risk factors for candidemia in hospitalized patients.

          Related collections

          Most cited references29

          • Record: found
          • Abstract: not found
          • Article: not found

          MatchIt: Nonparametric Preprocessing for Parametric Causal Inference

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis

              Background Bacterial co-pathogens are commonly identified in viral respiratory infections and are important causes of morbidity and mortality. The prevalence of bacterial infection in patients infected with SARS-CoV-2 is not well understood. Aims To determine the prevalence of bacterial co-infection (at presentation) and secondary infection (after presentation) in patients with COVID-19. Sources We performed a systematic search of MEDLINE, OVID Epub and EMBASE databases for English language literature from 2019 to April 16, 2020. Studies were included if they (a) evaluated patients with confirmed COVID-19 and (b) reported the prevalence of acute bacterial infection. Content Data were extracted by a single reviewer and cross-checked by a second reviewer. The main outcome was the proportion of COVID-19 patients with an acute bacterial infection. Any bacteria detected from non-respiratory-tract or non-bloodstream sources were excluded. Of 1308 studies screened, 24 were eligible and included in the rapid review representing 3338 patients with COVID-19 evaluated for acute bacterial infection. In the meta-analysis, bacterial co-infection (estimated on presentation) was identified in 3.5% of patients (95%CI 0.4–6.7%) and secondary bacterial infection in 14.3% of patients (95%CI 9.6–18.9%). The overall proportion of COVID-19 patients with bacterial infection was 6.9% (95%CI 4.3–9.5%). Bacterial infection was more common in critically ill patients (8.1%, 95%CI 2.3–13.8%). The majority of patients with COVID-19 received antibiotics (71.9%, 95%CI 56.1 to 87.7%). Implications Bacterial co-infection is relatively infrequent in hospitalized patients with COVID-19. The majority of these patients may not require empirical antibacterial treatment.
                Bookmark

                Author and article information

                Journal
                Crit Care Explor
                Crit Care Explor
                CC9
                Critical Care Explorations
                Lippincott Williams & Wilkins (Hagerstown, MD )
                2639-8028
                13 September 2022
                September 2022
                : 4
                : 9
                : e0762
                Affiliations
                [1 ] Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ.
                [2 ] Newark Beth Israel Medical Center, Newark, NJ.
                [3 ] Touro College of Pharmacy, New York, NY.
                [4 ] Cooperman Barnabas Medical Center, Livingston, NJ.
                [5 ] Division of Infectious Disease, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.
                [6 ] University of Washington, School of Pharmacy, Seattle, WA.
                [7 ] Division of Pulmonary and Critical Care Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.
                [8 ] SUNY Downstate Medical Center, Brooklyn, NY.
                Author notes
                For information regarding this article, E-mail: ddixit@ 123456pharmacy.rutgers.edu
                Article
                00012
                10.1097/CCE.0000000000000762
                9473786
                36119397
                934c8d3e-d29b-4fdb-a6d3-9b137e489b37
                Copyright © 2022 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine.

                This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

                History
                Categories
                Observational Study
                Custom metadata
                TRUE

                candidemia,co-infection,covid-19,severe acute respiratory syndrome coronavirus 2 infection

                Comments

                Comment on this article